The DOI matches its Crossref record; 79 of the 82 references it cites were found in a registry or an index.
Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020)
Open accessAbstract
Background & aims Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with a rapidly changing landscape of treatments. In the past 20 years, numerous randomized controlled trials (RCTs) have aimed at improving outcomes across disease stages. We aimed to analyze the current evidence and identify potential factors influencing response to therapies.Methods We conducted a systematic review of phase III RCTs (2002-2020) across disease stages. A meta-analysis was designed to examine the relationship between etiology and outcome after systemic therapies with either tyrosine-kinase inhibitor (TKI)/antiangiogenic or immune checkpoint inhibitor (ICI) therapy.Results Out of 10,100 studies identified, 76 were phase III RCTs. Among them, a rigorous screening algorithm identified 49 with high quality including a total of 22,113 patients undergoing adjuvant (n = 7) and primary treatment for early (n = 2), intermediate (n = 7), and advanced (first-line, n = 21; second-line, n = 12) stages of disease. Nine of these trials were positive, 6 treatments have been adopted in guidelines (sorafenib [2 RCTs], lenvatinib, atezolizumab+bevacizumab, regorafenib, cabozantinib and ramucirumab), but 2 were not (adjuvant CIK cells and sorafenib plus hepatic arterial infusion with FOLFOX). Meta-analysis of 8 trials including 3739 patients revealed ICI therapy to be significantly more effective in patients with viral hepatitis compared with nonviral-related HCC, whereas no differences related to etiology were observed in patients treated with TKI/anti-vascular endothelial growth factor.Conclusions Among 49 high-quality RCTs conducted in HCC during 2002-2020, 9 resulted in positive results. A meta-analysis of systemic therapies suggests that immunotherapies may be more effective in viral etiologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“those testing such approaches in HCC after potentially curative resection or local ablation have not yielded positive results over the preceding decades11.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In summary, most of the studies failed to identify any clinical benefit and, among the positive studies, validation in trials conducted in Western countries is awaited.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In KEYNOTE-240, OS benefits seem numerically greater in patients with HBV-HCC (HR 0.57 [0.35–0.94]) treated with pembrolizumab compared to placebo, while the HR of patients with non-viral HCCs was 0.88 (0.64–1.20) [46].”
From Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis (2025) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In KEYNOTE-240, OS benefits seem numerically greater in patients with HBV-HCC (HR 0.57 [0.35–0.94]) treated with pembrolizumab compared to placebo, while the HR of patients with non-viral HCCs was 0.88 (0.64–1.20) [46].”
From Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis (2025) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the HR for PFS was similar (0.70 [0.44–1.13] and 0.75 [0.56–1.01]) respectively.”
From Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis (2025) · cites this paper as [46]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in CheckMate-459, KEYNOTE-240, and COSMIC-312, the apparent reduced benefit from ICIs for patients with non-viral HCCs was likely a major cause for the negative OS outcomes, despite a clear benefit for patients with HBV-HCCs [27, 35, 46]”
From Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis (2025) · cites this paper as [46]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Results from other studies suggest that a metabolic-related fatty liver disease-related aetiology might be related to a decreased response owing to unique immunological traits hampering antitumoural surveillance11,101.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Only a small number of patients with HCV-HCC were recruited (15.5% of all).”
From Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis (2025) · cites this paper as [46]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationAtezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S. A., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,173
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Marrero, J. A., Kulik, L., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,597
Cited by
Sorted by citations
Items 101–200 of 249
Costante, F., Airola, C., Santopaolo, F., Gasbarrini, A., Pompili, M., & Ponziani, F. R. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i9.1622 · Cited by 12
Development and validation of prognostic nomograms for large hepatocellular carcinoma after HAIC
Yao, W., Wei, R., Jia, J., Li, W., Zuo, M., Zhuo, S., Shi, G., Wu, P., & An, C. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231163845 · Cited by 11
Han, J., Kuai, W., Yang, L., Tao, X., Wang, Y., Zeng, M., Li, Y., Mi, Y., Zhang, N., Lu, W., et al. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0048 · Cited by 11
Diao, Y., Sun, L., Wang, M.-D., Han, J. S., Zeng, Y., Yao, L., Sun, X.-D., Li, C., Shao, G., Gu, L., et al. (2024) · Surgery · doi:10.1016/j.surg.2024.03.028 · Cited by 10
Hepatocellular Carcinoma Intrinsic Cell Death Regulates Immune Response and Prognosis
Re, V. D., Rossetto, A., Rosignoli, A., Muraro, E., Racanelli, V., Tornesello, M. L., Zompicchiatti, A., & Uzzau, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.897703 · Cited by 13
Ding, Z., Meng, G.-X., Xue, J.-S., Liu, H., Yang, L.-S., Li, R., Mao, X., Yan, Y., Wang, D., Dong, Z., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103940 · Cited by 10
de Mattos, Â. Z., Debes, J. D., Vogel, A., Arrese, M. A., Revelo, X. S., Pase, T. H. S., Manica, M., & de Mattos, Â. A. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i28.3595 · Cited by 10
Metabolic-immune microenvironment crosstalk mediating ICI resistance in MASH-HCC
Ju, Y., Xu, K., Chen, X., Wu, T., & Yuan, Y. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.06.008 · Cited by 11
Niu, D., Wang, D., Fan, L., Liu, Z., Chen, M., Zhang, W., Liu, Y., Xu, J., & Liu, Y. (2023) · Environmental Toxicology · doi:10.1002/tox.23771 · Cited by 9
Cai, C., Yang, L., & Zhou, K. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-02057-0 · Cited by 9
Zhang, J.-X., Chen, Y.-X., Zhou, C., Liu, J., Liu, S., Shi, H., & Zu, Q. (2022) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2022/7982118 · Cited by 9
Li, L., Liu, H.-T., Teng, Y., Deng, Z., Zhang, G.-L., Su, J., Ma, L., & Zhong, J. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2151891 · Cited by 9
Ye, Y., Wang, Y., Xu, H., & Yi, F. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02955-5 · Cited by 12
Vachliotis, I. D., Valsamidis, I., & Pοlyzos, S. A. (2023) · Cancers · doi:10.3390/cancers15215306 · Cited by 9
Emerging drugs for the treatment of hepatocellular carcinoma
Ayoub, W. S., Jones, P. D., Yang, J. D., & Martin, P. B. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2083107 · Cited by 8
Yan, T., Huang, C., Peng, C., Duan, X., Ji, D., Duan, Y., Zhang, W., Zhao, H., Gao, K., Yang, X., et al. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-6614 · Cited by 8
Papadopoulos, G., Giannousi, E., Avdi, A. P., Velliou, R.-I., Nikolakopoulou, P., & Chatzigeorgiou, A. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1343806 · Cited by 8
Payo‐Serafín, T., Méndez‐Blanco, C., Fernández‐Palanca, P., Martínez‐Geijo, J., Reviejo, M., de Urbina, J. J. O., González‐Gallego, J., Marín, J. J. G., Mauriz, J. L., & San‐Miguel, B. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3312 · Cited by 8
Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers
Gonzalez, N. S., Castet, F., Élez, E., Macarulla, T. M., & Tabernero, J. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1021772 · Cited by 9
Self-citationGüven, D. C., Erul, E., Şahin, T. K., Dızdar, Ö., Yalçın, Ş., & Şahin, İ. H. (2022) · Future Oncology · doi:10.2217/fon-2022-0642 · Cited by 9
Wang, Y., Lau, W. Y., Li, Y., Tian, Y., Lei, Y., Wang, J., & Xia, F. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000652 · Cited by 8
Immunotherapy for HCC: limitations in patients with NASH
Agarwal, P. D., Lucey, M. R., Said, A., & Kratz, J. D. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100886 · Cited by 8
ANXA5: A Key Regulator of Immune Cell Infiltration in Hepatocellular Carcinoma
Wang, W., Liu, D., Yao, J., Yuan, Z., Liang, Y., & Cao, B. (2024) · Medical Science Monitor · doi:10.12659/msm.943523 · Cited by 7
Qu, Y. A., Huang, J. C. N., Wang, Z. V., Ferguson, A. L., Nguyen, J. M. H. N., Zhang, M. N., Osborne, K., Boumelhem, B. B., McCaughan, G. W., Liu, K., et al. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl44837 · Cited by 8
Klink, A. J., Marshall, L., Aly, A., Seal, B. S., Healey, M. J., & Feinberg, B. A. (2022) · The Oncologist · doi:10.1093/oncolo/oyab059 · Cited by 7
Chen, S., Liu, J., Zhang, S., Zhao, L., Zhang, J., Han, P., Zhang, Q., Liu, Y., Wang, F., & Li, J. (2024) · Environmental Toxicology · doi:10.1002/tox.24177 · Cited by 7
Decraecker, M., Toulouse, C., & Blanc, J. (2021) · Cancers · doi:10.3390/cancers13246310 · Cited by 7
Luo, M., Sun, H., Jiang, Q., Chai, Y., Li, C., Yang, B., & Hong, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.777356 · Cited by 7
Liu, W., Xie, Z., Shen, K., Jiang, L., Liu, C. H., Ge, Y., Yu, J., Jia, W., Ma, J., & Chen, H. (2023) · Medical Oncology · doi:10.1007/s12032-023-02082-x · Cited by 7
Chen, W., Chen, F., Gong, M., Ye, L., Weng, D., Jin, Z., & Wang, J. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02604-4 · Cited by 7
Management of autoimmune and viral hepatitis in immunotherapy: a narrative review
Kuo, L., Kuwelker, S., & Tsai, E. (2023) · Annals of Palliative Medicine · doi:10.21037/apm-23-250 · Cited by 6
Fu, J., Wei, Y., Yang, Y., Yang, X., Ouyang, T., Wang, X., Chen, S., Liu, Z., Su, Y., Fu, J., et al. (2025) · 癌症：英文版 · doi:10.1002/cac2.70061 · Cited by 6
Trépo, E., Zucman‐Rossi, J., & Nault, J. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01175-y · Cited by 6
Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma
Foy, V., McNamara, M. G., Valle, J. W., Lamarca, Á., Edeline, J., & Hubner, R. A. (2023) · Current Oncology · doi:10.3390/curroncol30090628 · Cited by 6
Ng, K. Y. Y., Teo, A. E., Tan, S. H., Tan, J. J. E., Tay, D. S. H., Lee, A. W. X., Ang, A. J. S., Wong, L. W. J., Choo, S. P., Toh, H. C., et al. (2024) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.14139 · Cited by 6
Haghnejad, V., Müller, M., Blaise, L., Gerolami, R., Bouattour, M., Assénat, E., Manfrédi, S., Péron, J., Burcheri, A., Lopez, A., et al. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.03.005 · Cited by 6
Li, D., Li, J., Yu, F., Wang, B., & Liu, B. (2023) · Oncology Letters · doi:10.3892/ol.2023.13811 · Cited by 6
Hao, X., Li, J., Liu, B., Jing, W., Guo, Y., Liu, F., Li, X., Chen, X., Yuan, Y., & Ma, W. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101160 · Cited by 6
Bracchiglione, J., Rodríguez-Grijalva, G., Requeijo, C., Santero, M., Salazar, J., Salas-Gama, K., Meade, A.-G., Antequera, A., Auladell-Rispau, A., Quintana, M. J., et al. (2023) · Cancers · doi:10.3390/cancers15030766 · Cited by 6
Atezolizumab Plus Bevacizumab in Advanced HCC: Efficacy in NASH-Specific Etiology
Llovet, J. M., & Heikenwälder, M. F. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.04.014 · Cited by 6
Self-citationChen, Y., Jia, L., Li, Y., Cui, W., Wang, J., Zhang, C., Bian, C., & Luo, T. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1364345 · Cited by 6
Lee, H. A. (2024) · Ewha Medical Journal · doi:10.12771/emj.2024.e65 · Cited by 5
Liu, B., Yin, L., Chen, Y., Hou, X., Li, Y., Liu, X., & Liu, R. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1615506 · Cited by 5
Li, D., & Zhang, X. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000846 · Cited by 8
Zhu, H., Zhao, S., Zhao, T., Chen, L., Li, S., Ji, K., Jiang, K., Tao, H., Xuan, J., Yang, M., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28497 · Cited by 5
Strategies to enhance the response of liver cancer to pharmacological treatments
Marín, J. J. G., Macías, R. I. R., Asensio, M., Romero, M. R., Temprano, Á. G., Pereira, O. R., Jimenez, S., Mauriz, J. L., Giacomo, S. D., Avila, M. A., et al. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00176.2024 · Cited by 7
Cowzer, D., Chou, J. F., Walch, H. S., Keane, F., Khalil, D. N., Shia, J., Do, R. K. G., Yarmohammadi, H., Erinjeri, J. P., Dika, I. E., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae110 · Cited by 5
Wong, C. H. L., Chan, S.-K., Lo, R. C., & Chiang, C. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104842 · Cited by 5
Yao, N., Jiang, W. I., Wang, Y., Song, Q., Cao, X., Zheng, W., & Zhang, J. (2023) · European journal of medical research · doi:10.1186/s40001-023-01091-w · Cited by 5
First-Line Treatment for Advanced Hepatocellular Carcinoma: A Three-Armed Real-World Comparison
Mahn, R., Glüer, O. A., Sadeghlar, F., Möhring, C., Zhou, T., Anhalt, T., Monin, M. B., Kania, A., Glowka, T. R., Feldmann, G., et al. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s432948 · Cited by 5
Xu, B., Li, M., Weng, N., Zhou, C., Chen, Y., Wei, J., & Fu, L. (2024) · Biomedicines · doi:10.3390/biomedicines12020267 · Cited by 5
Battista, D. D., Yakymi, R., Scheibe, E., Sato, S., Gerstein, H., Markowitz, T. E., Lack, J., Mereu, R., Manieli, C., Zamboni, F., et al. (2024) · Cancers · doi:10.3390/cancers16071370 · Cited by 5
Wu, Q., Li, P., Tao, X., Lin, N., Mao, B., & Xie, X. (2024) · BMC Cancer · doi:10.1186/s12885-024-12874-7 · Cited by 5
Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021
Brown, Z. J., Hewitt, D. B., & Pawlik, T. M. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2079491 · Cited by 6
Shi, J., Zhang, H., Han, G., Wang, J., Han, X., Zhao, M., Duan, X., Mi, L., Li, N., Yin, X., et al. (2023) · PubMed Central · Cited by 4
Petrelli, F., Colombo, S., Dottorini, L., Ghilardi, M., Giorgi, A. D., Tomasello, G., Carcano, G., & Ghidini, M. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105248 · Cited by 4
Akkuş, E., & Yaşar, H. A. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70318 · Cited by 4
The versatile interplay between steatotic liver disease and liver cancer
Rahbari, M., Gris‐Oliver, A., Ramadori, P., Aicher, D., Sia, D., MALEK, N. P., Loomba, R. S., Bataller, R. A., Llovet, J. M., & Heikenwälder, M. F. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00918-y · Cited by 4
Self-citationZhang, W., Zhao, Y., He, Q., & Lang, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1211126 · Cited by 4
Shi, Y., Wang, Q., Huang, L., Li, N., Ren, X., & Bi, S. (2024) · International Wound Journal · doi:10.1111/iwj.14545 · Cited by 4
RetractedZhang, S., Yang, G., Song, R., Wang, W., Meng, F., Yin, D., Wang, J., Zhang, S., Cai, W. L., Liu, Y., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241258394 · Cited by 8
Xing, R., Gan, J., Mei, J., Li, Z., & Xu, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1619387 · Cited by 4
Qi, L., Hu, B., Cao, C., Peng, T., Xu, M., Liu, S., Xu, Y., Liu, X., Ding, W., Li, L., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118515 · Cited by 4
Brown, Z. J., Gregory, S., Hewitt, D. B., Iacono, S. A., Choe, J. K., Labiner, H. E., & Pawlik, T. M. (2022) · Surgical Oncology · doi:10.1016/j.suronc.2022.101748 · Cited by 4
Huang, C., & Hsieh, S. (2023) · Hepatology · doi:10.1097/hep.0000000000000393 · Cited by 4
Peng, W., Pan, Y., Xie, L., Yang, Z., Ye, Z., Chen, J., Wang, J., Hu, D., Xu, L., Zhou, Z., et al. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241237631 · Cited by 5
Iwamoto, H., Niizeki, T., Nagamatsu, H., Ueshima, K., Tani, J., Kuzuya, T., Kasai, K., Kooka, Y., Hiraoka, A., Sugimoto, R., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1811231/v1 · Cited by 4
Zhang, W., Zhao, X., Gao, W., Si, T., Zou, Q., Yang, X., Xing, W., & Yu, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1596864 · Cited by 3
Sorafenib with or without co-interventions for hepatocellular carcinoma
Chen, S., Liu, J., Li, X., Dang, S., & Li, W. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015851 · Cited by 3
Jiang, P., Li, F., Jiang, Z., Sun, Y., Yang, F., Chu, L.-S., Gai, Y., & Wang, H. (2025) · Oncology Letters · doi:10.3892/ol.2025.15183 · Cited by 3
Pioneering precision: The evolution of immunotherapy for hepatocellular carcinoma
Foerster, F., Wiesmann, L., Bark, P., & Galle, P. R. (2025) · Hepatology · doi:10.1097/hep.0000000000001554 · Cited by 3
Xie, W., Sun, L., Fu, Y., Liu, Y., Wang, J., & Liu, L. (2025) · Academic Radiology · doi:10.1016/j.acra.2025.10.048 · Cited by 3
SOX4-STAT6-MTHFD2 axis drives hepatocellular carcinoma progression and treatment resistance
Tsai, C.-L., Yu, M., Hsu, C., Tang, H.-Y., Lee, Y., Chi, L., Lin, S., Cheng, M., Hsu, H.-Y., & Tsai, C. (2026) · Cell Death and Disease · doi:10.1038/s41419-025-08394-2 · Cited by 3
Hazari, M. W. A. D., Nandi, S., & Das, C. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153656 · Cited by 3
Elsheikh, M., Ibrahim, M. A., Fares, S., Bhongade, M., Adhem, K., Ramirez-Morales, X. I., Kaseb, A. O., Petrosino, J. F., Hassan, M. M., & Jalal, P. K. (2026) · Cancer Medicine · doi:10.1002/cam4.71738 · Cited by 3
Izzo, F., Mason, M. C., Silberfein, E. J., Massarweh, N. N., Hsu, C., Cao, H. S. T., Palaia, R., Piccirillo, M., Belli, A., Patrone, R., et al. (2022) · Biology · doi:10.3390/biology11111597 · Cited by 3
Chang, X., Yu, S., Pang, J., Zhang, W., Kong, H., Huang, J., Zhang, G., Zhang, H., Gu, Y., Chen, Y., et al. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s411748 · Cited by 3
la Garza‐Ramos, C. D., Montazeri, S. A., Musto, K. R., Kapp, M. D., Lewis, A. R., Frey, G. T., Paz‐Fumagalli, R., Ilyas, S. I., Harnois, D. M., Majeed, U., et al. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s414853 · Cited by 3
Zhou, J. Y., Eder, D., Weber, F., Heumann, P., Kronenberg, K., Werner, J. M., Geissler, E. K., Schlitt, H. J., Hutchinson, J. A., & Bitterer, F. (2023) · Frontiers in Transplantation · doi:10.3389/frtra.2023.1211916 · Cited by 3
Zhang, J., Yu, H., & Li, G. (2024) · Biointerphases · doi:10.1116/6.0003204 · Cited by 3
Jolkinolide B inhibits the progression of hepatocellular carcinoma by regulating Musashi-2 protein
Wu, T., Yang, H., Li, J., Fang, H., Shi, X., Li, J., & Feng, L. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299920 · Cited by 3
Akiba, J., Ogasawara, S., & Yano, H. (2024) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20445 · Cited by 3
Zuo, M., An, C., Cao, Y.-Z., Pan, J., Xie, L.-P., Yang, X., Li, W., & Wu, P. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i8.3481 · Cited by 3
Systemic treatment of hepatocellular carcinoma secondary to non-alcoholic fatty liver disease
Rzeniewicz, K., & Sharma, R. (2024) · World Journal of Clinical Oncology · doi:10.5306/wjco.v15.i11.1394 · Cited by 3
Chrysavgis, L., & Cholongitas, Ε. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21938-2.00020-5 · Cited by 3
Cammarota, A., Zanuso, V., D’Alessio, A., Pressiani, T., Bozzarelli, S., Personeni, N., & Rimassa, L. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2042253 · Cited by 4
Sun, F. S. K., Wong, J. S. L., Mak, L.-Y., Wong, C. C.-L., Chew, V., Li, B. C. W., Leung, R., Cheung, T. T., & Yau, T. (2025) · Liver Cancer · doi:10.1159/000548536 · Cited by 3
Yu, D., Chen, H., & Wang, L. (2025) · Cancer Reports · doi:10.1002/cnr2.70244 · Cited by 2
Lee, K., Kim, S., Zhao, J., & Neo, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1631258 · Cited by 2
Cui, L., Liu, J., Lv, Y., Chen, B., Liu, K.-J., & Bu, Y. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl45454 · Cited by 3
Kang, F., Wang, Y., Cai, F.-H., Wu, L., Wang, H., Han, L., Yin, Q., Bai, L., & Bian, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1697949 · Cited by 2
The evolving role of selective internal radiation therapy in hepatocellular carcinoma
Faggian, G., Faggian, R., Salzano, M., Stavolo, C., Argenziano, T., Argenziano, A., Diglio, A., & Faggian, A. (2026) · Italian Journal of Medicine · doi:10.4081/itjm.2026.2414 · Cited by 2
Hepatocellular Carcinoma – from Immunobiology to Immunotherapy
Roehlen, N., Bengsch, B., Rennert, C., Schultheiß, M., & Thimme, R. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2722-5684 · Cited by 2
Agrawal, D., Jothimani, D. K., Bhoori, S., Reddy, G. N., Saigal, S., Rela, M., & Mazzaferro, V. (2026) · Hepatology International · doi:10.1007/s12072-026-11097-1 · Cited by 2
Immunotherapy in HCC: aetiology matters
Ng, I. O., & Lyu, G. (2026) · eGastroenterology · doi:10.1136/egastro-2026-100465 · Cited by 2
Castria, T. B. D., & Kim, R. D. (2024) · Pragmatic and Observational Research · doi:10.2147/por.s395974 · Cited by 2
Wang, Y., Lau, W. Y., Li, Y., Tian, Y., Lei, Y., Feng, X., & Wang, J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0306869 · Cited by 2
Guo, D., Zhang, S., Yang, M., Xu, Y., Wang, P., Guo, W., Huang, X., Fan, J., Zhou, J., Yang, X., et al. (2025) · Hepatology Research · doi:10.1111/hepr.14154 · Cited by 2
Bahirwani, J. T., Ahuja, S. J. K., Changela, M., Patel, H. D., Patel, N., Kaneriya, M., & Patel, V. N. (2025) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2025.04.003 · Cited by 2
Ainiwaer, A., Chen, Y., & Lu, Y. (2024) · Hepatoma Research · doi:10.20517/2394-5079.2023.155 · Cited by 2
Metadata
- Authors
- Haber, P. K., Puigvehí, M., Castet, F., Lourdusamy, V., Montal, R., Tabrizian, P., Buckstein, M., Kim, E., Villanueva, A., Schwartz, M., & Llovet, J. M.
- Affiliations
- Tisch Cancer Institute (US)
- Universitat Autònoma de Barcelona (ES)
- Hospital Clínic de Barcelona (ES)
- Hospital Universitari Arnau de Vilanova (ES)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Llovet, Josep M.
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 161
- Issue
- 3
- Pages
- 879-898
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC12276942
- OpenAlex
- W3169705253
- Cited by
- 248
- References
- 82
- Citations by year
- 2026: 33 · 2025: 42 · 2024: 52 · 2023: 67 · 2022: 39 · 2021: 13
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Repositori digital de la UPF (Universitat Pompeu Fabra) (submittedVersion)
- Funders
- U.S. Department of Defense (CA150272P3)
- National Cancer Institute (P30 CA19652, R01 CK 128289-01)
- Samuel Waxman Cancer Research Foundation
- California Department of Fish and Game
- Agència de Gestió d'Ajuts Universitaris i de Recerca (SGR-1358)
- Ministerio de Ciencia e Innovación (SAF-2016-76390)
- Deutsche Forschungsgemeinschaft (HA 8754/1-1)
- Fundación Científica Asociación Española Contra el Cáncer
- Generalitat de Catalunya
- Asociación Española para el Estudio del Hígado
- Cancer Research UK
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- hepatocellular carcinoma, systemic therapy, tyrosine kinase inhibitors, immune checkpoint inhibitors, viral hepatitis etiology, sorafenib, lenvatinib, atezolizumab, bevacizumab, regorafenib, cabozantinib, ramucirumab, adjuvant therapy, treatment response
- MeSH terms
- Progression-Free Survival, Immune Checkpoint Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Hepatocellular, Humans, Immunotherapy, Liver Neoplasms, Neoplasm Staging, Time Factors, Randomized Controlled Trials as Topic, Chemoembolization, Therapeutic, Chemotherapy, Adjuvant, Clinical Trials, Phase III as Topic, Disease Progression, Radiopharmaceuticals, Evidence-Based Medicine, Neoadjuvant Therapy, Ablation Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
